KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults.

Yan Wu, Xiao Long, Nanze Yu, Jin Chen, Jianyun Lu, Lina Tan, Wei Lai, Li Li, Sufan Wu, Liming Wu, Jiaming Sun, Hongsen Bi, Songmei Geng, Huiping Wang, Shengkang Luo, Zhiqi Hu, Jianmin Yang, Baoxi Wang, Wu Yang, Xiaoli Sun, Xiaoyun Sun

Aesthet Surg J 46(6) 672-679

PMID41692601
PMCIDPMC13182903
DOI10.1093/asj/sjag042
发表日期2026-02-15
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

BACKGROUND: Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk. OBJECTIVES: To evaluate the efficacy, safety, and immunogenicity of YY001, a recombinant botulinum toxin type A (Chongqing Claruvis Pharmaceutical Co., Ltd., Chongqing, China), in the treatment of moderate-to-severe glabellar lines. METHODS: In this multicenter, randomized, double-blind, vehicle- and active-controlled Phase III trial, 529 adults aged 18-65 with moderate to severe glabellar lines were randomized 4:2:1 to receive a single 20 U injection of YY001, Botox®(Allergan Pharmaceuticals Ireland, Westport, Ireland), or vehicle. The primary endpoint was composite response rate (CRR) at Week 4, defined as a ≥2-grade improvement of glabellar line severity assessed by both investigator and participant. Secondary endpoints included onset time, duration, satisfaction, and safety. RESULTS: YY001 achieved a CRR of 86.7% at Week 4, significantly outperforming Botox® (66.7%, P < .0001) and vehicle (1.3%, P < .0001). It showed faster onset, longer median duration (97 days), and high participant satisfaction. Adverse events were mild and comparable across groups. Only one case of anti-drug antibody was observed; no neutralizing antibodies were detected. A 12-week follow-up and ethnically homogenous population may limit generalizability. CONCLUSIONS: YY001 demonstrated strong efficacy and a favorable safety profile than Botox®. Longer-term and multicenter studies are needed to assess durability, immunogenicity, and applicability across broader populations. LEVEL OF EVIDENCE: 1 (THERAPEUTIC): For image description, please refer to the figure legend and surrounding text.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT-compliant participant flow diagram.
非 KM Figure
Figure 2Figure 2. Composite response rates (CRRs) at Week 1, Week 8, and Week 12, in which the CRR is defined as the proportion of participants achieving a glabellar line severity score of 0 or 1 and an improvement of at least 2 grades from baseline, based on both investigator and subject assessments during on-site visits.
非 KM Figure
Figure 3Figure 3. (A) Proportion of participants who achieved a score of 0 or 1 of glabellar line severity at maximum frown on the investigators’ assessments at Week 1, Week 4, Week 8, and Week 12; (B) Proportion of participants who achieved a score of 0 or 1 of glabellar line severity at maximum frown on the participants’ assessments at Week 1, Week 4, Week 8, and Week 12; (C) Proportion of participants who achieved a score of 0 or 1 of glabellar line severity at maximum frown on the photographic assessments conducted by the Independent Review Committee (IRC) at Week 1, Week 4, Week 8, and Week 12.
非 KM Figure
Figure 4Figure 4. Clinical photographs of a 33-year-old Chinese female participant treated with YY001. The participants had a baseline Investigator's and Subject's FWS score of 3 and achieved a score of 0 at both Weeks 4 and 12 post-treatment. (A) Baseline; (B) Week 4 post-treatment; (C) Week 12 post-treatment.
非 KM Figure
Figure 5Figure 5. Clinical photographs of a 25-year-old Chinese female participant treated with YY001. The participants had a baseline Investigator's and Subject's FWS score of 3 and achieved a score of 0 at both Weeks 4 and 12 post-treatment. (A) Baseline; (B) Week 4 post-treatment; (C) Week 12 post-treatment.
非 KM Figure
Figure 6Figure 6. Clinical photographs of a 21-year-old Chinese female participant treated with YY001. The participants had a baseline Investigator's and Subject's FWS score of 3 and achieved a score of 0 at both Weeks 4 and 12 post-treatment. (A) Baseline; (B) Week 4 post-treatment; (C) Week 12 post-treatment.
非 KM Figure